NASDAQ OMX

Merus Announces Data from a Phase 1/2 Study of MCLA-128 to be Presented at the 2017 American Society of Clinical Oncology Annual Meeting

20.4.2017 22:05 | NASDAQ OMX

Dela

UTRECHT, The Netherlands, April 20, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that data from a Phase 1/2 study of MCLA-128 for the treatment of metastatic breast cancer will be presented in a poster session at the American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held on June 2-6, 2017 in Chicago, Illinois.

Details of the poster presentation are as follows:

Title: First-in-human phase 1/2 study of MCLA-128, a full length IgG1 bispecific antibody targeting HER2 and HER3: Final phase 1 data and preliminary activity in HER2+ metastatic breast cancer (MBC)
Abstract Number: 2522
Poster Session: Developmental Therapeutics-Clinical Pharmacology and Experimental Therapeutics
Date and Time: Monday, June 5, 2017, 8:00 AM-11:30 AM CT

About MCLA-128
MCLA-128 is designed to block HER3/heregulin dependent tumor growth and survival as well as enhance immune-mediated killing of tumors. MCLA-128 employs a 'dock and block' mechanism in which the mode of HER2 receptor binding orientates the HER3 binding arm to effectively block oncogenic signaling through the HER2:HER3 heterodimer even under high heregulin concentrations. In addition, MCLA-128 is engineered for enhanced ADCC in order to recruit and activate immune effector cells to directly kill the tumor.

About Merus N.V.
Merus is a clinical-stage immuno-oncology company developing innovative full length human bispecific antibody therapeutics, referred to as Biclonics®. Biclonics® are based on the full-length IgG format, are manufactured using industry standard processes and have been observed in preclinical studies to have several of the same features of conventional monoclonal antibodies, such as long half-life and low immunogenicity. Merus' lead bispecific antibody candidate, MCLA-128, is being evaluated in a Phase 1/2 clinical trial in Europe as a potential treatment for HER2-expressing solid tumors. Merus' second bispecific antibody candidate, MCLA-117, is being developed in a Phase 1/ 2 clinical trial in patients with acute myeloid leukemia. The Company also has a pipeline of proprietary bispecific antibody candidates in preclinical development, including MCLA-158, which is designed to bind to cancer stem cells and is being developed as a potential treatment for colorectal cancer and other solid tumors, and Biclonics® designed to bind to various combinations of immunomodulatory molecules, including PD-1 and PD-L1.

Forward Looking Statement
Except for the historical information set forth herein, this press release contains predictions, estimates and other forward-looking statements, including without limitation statements regarding: the impact of the collaboration on Merus' finances and clinical development, whether any of the programs under the collaboration will be successful; and whether and when Merus will receive any of the expected or potential payments under the collaboration and the amounts of such payments to Merus. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from our expectations, including unanticipated developments in and risks related to: research and development efforts related to the collaboration programs; the clinical development process, which is expensive and unpredictable; the possibility that results of clinical trials may be unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; other market or economic factors; unanticipated delays; Merus' ability to compete against parties with greater financial or other resources; Merus' ability to commercialize and market its products, if approved; greater than expected expenses; and the other important factors detailed in Merus' final prospectus filed with the Securities and Exchange Commission, or SEC, on May 20, 2016 relating to our Registration Statement on Form F-1, and its other reports filed with the SEC. Merus disclaims any intent or obligation to update these forward-looking statements. These forward-looking statements should not be relied upon as representing Merus' views as of any date subsequent to the date of this press release.

Contacts:
Media:
Eliza Schleifstein
+1 973 361 1546
eliza@argotpartners.com

Investors:
Kimberly Minarovich
+1 646 368 8014
kimberly@argotpartners.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Merus N.V. via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Skriv in din e-postadress så får du ett mejl när vi har något nytt att berätta.

Senaste nyheterna från NASDAQ OMX

TGS and PGS Announce Fourth 3D Seismic Project Offshore Eastern Canada26.5.2017 07:50

ASKER, Norway, May 26, 2017 (GLOBE NEWSWIRE) -- TGS and Petroleum Geo-Services ("PGS") announce the fourth 3D seismic project offshore Eastern Canada for 2017. Long Range 3D will comprise approximately 9,100 km2 of 3D GeoStreamer® data in the Eastern Newfoundland region. The survey covers open acreage which will be included in the November 2018 licensing round under Newfoundland and Labrador's Scheduled Land Tenure system. Following completion of these surveys, the jointly-owned library will have more than 175,000 km of 2D GeoStreamer data and 28,500 km2 of 3D GeoStreamer data. An expansive well log library is also available in the region, along with advanced multi-client interpretation products that will improve play, trend and prospect delineation. "With four 3D projects now committed for 2017 this will be our most active year ever in Newfoundland and Labrador. E&P companies are continuing to prioritize this region in their exploration strat

Mandalay Resources Corporation går ut med slutförande av reviderat Återköpserbjudande och begäran om medgivande gällande 5,875 % säkerställda utbytbara skuldebrev25.5.2017 13:46

TORONTO 24 maj 2017 (GLOBE NEWSWIRE) -- Mandalay Resources Corporation ("Mandalay" eller "Bolaget") (TSX:MND) meddelade idag att Gold Exchange Limited ("GEL"), ett självständigt företag för särskilda ändamål som är registrerat i Jersey, har ingått avtal gällande ett reviderat återköpserbjudande ("Återköpet") och en begäran om medgivande ("Begäran om medgivande") för sitt kapitalbelopp på 60 000 000 USD, 5,875 % säkerställda utbytbara skuldebrev som löper ut 2019 ("Skuldebreven"). GEL gav ut Skuldebreven 2014 och lånade ut inkomsterna till ett av Bolagets dotterbolag i enlighet med villkoren för låneavtalet och relaterad finansieringsöverenskommelse ("Lånet") som tillsammans speglar de huvudsakliga villkoren för Skuldebreven. Som angivet i Mandalays pressmeddelande från den 12 maj 2017, slutfördes inte det ursprungliga återköpserbjudandet och begäran om medgivande som GEL lanserade gällande Skuldebreven

Karolinska Development's Annual General Meeting 201724.5.2017 20:00

STOCKHOLM - May 24, 2017. At the Annual General Meeting of Karolinska Development AB held May 24, 2017, the following resolutions were passed: Profit and loss statement and the balance sheet: It was resolved to adopt the profit and loss statement and the balance sheet and the consolidated profit and loss statement and the consolidated balance sheet. Appropriation of the company's result: It was resolved to approve the allocation of the result, proposed by the board and the CEO, in total SEK -12 406 768 be allocated as follows: To be carried forward SEK -12 406 768. Discharge from liability of the directors and the CEO: It was resolved to grant the directors and the CEO discharge from liability for the financial year 2016. Resolution regarding the number of directors and auditors and deputy auditors to be appointed: It was resolved that the number of directors shall be seven without deputies and that the number

Karolinska Developments årsstämma 201724.5.2017 20:00

STOCKHOLM den 24 maj 2017. Vid Karolinska Developments årsstämma som hölls den 24 maj 2017 beslutade aktieägarna, följande: Redovisning: beslutades att fastställa av resultaträkning och balansräkning samt koncernresultaträkning och koncernbalansräkning. Resultatdisposition:  beslöts att godkänna styrelsens och verkställande direktörens förslag att till årsstämmans förfogande stående medel, sammanlagt SEK -12 406 768, disponeras enligt följande: SEK -12 406 768 balanseras i ny räkning. Ansvarsfrihet för styrelsens ledamöter och VD: beslöts att bevilja styrelsen och verkställande direktören ansvarsfrihet för verksamhetsåret 2016. Fastställande av antalet styrelseledamöter samt revisorer och revisorssuppleanter: Beslöts att antalet ledamöter i styrelsen skall vara sju utan suppleanter samt att antalet revisorer skall vara en utan suppleanter. Fastställande av arvoden till styrelsen och revisorerna: bes

Nasdaq to Deliver Post-Trade Technology to Depósito Central de Valores (DCV)24.5.2017 15:00

The Chilean central securities depository (CSD) will boost its infrastructure capabilities and increase efficiencies with fully-fledged CSD solution based on the Nasdaq Financial Framework NEW YORK and SANTIAGO, Chile, May 24, 2017 (GLOBE NEWSWIRE) -- Nasdaq, Inc. (Nasdaq:NDAQ) and Depósito Central de Valores (DCV)  today announced a new landmark agreement to bolster the technological infrastructure of Chile's central securities depository (CSD). "We are very satisfied with our thorough, year-long vendor partnership process in selecting the Nasdaq platform, which will replace the core system of the DCV," said Fernando Yáñez, CEO of DCV. "We believe with the implementation of this new system, we will have more opportunities for growth and diversification in our current services, as well as strengthening our day-to-day operations." Under the agreement with DCV, Nasdaq will deliver its CSD Solution, which will allow for:

Mandalay Resources Corporation Announces Completion of Revised Repurchase Offer and Consent Solicitation in Respect of 5.875% Secured Exchangeable Bonds24.5.2017 14:11

TORONTO, May 24, 2017 (GLOBE NEWSWIRE) -- Mandalay Resources Corporation ("Mandalay" or the "Company") (TSX:MND) announced today that Gold Exchange Limited ("GEL"), an unaffiliated special purpose vehicle incorporated in Jersey, has entered into agreements with respect to a revised repurchase offer (the "Repurchase") and consent solicitation (the "Consent Solicitation") in respect of its U.S.$60,000,000 principal amount 5.875% secured exchangeable bonds due 2019 (the "Bonds"). GEL issued the Bonds in 2014 and loaned the proceeds to a subsidiary of the Company pursuant to the terms of a loan agreement and related funding agreement (the "Loan") which together mirror the principal terms of the Bonds. As indicated in Mandalay's press release of May 12, 2017, the original repurchase offer and consent solicitation that GEL launched in respect of the Bonds on April 19, 2017 (the "Original Proposed

I vårt nyhetsrum kan du läsa de senaste nyheterna, få tillgång till pressmaterial och hitta kontaktinformation.Besök vårt nyhetsrum